• PTA Negative Stain: Five Evidence Questions

  2026-10-08

  A source-grounded overview of negative-stain electron microscopy, the evidence surrounding conserved coronavirus glycans, and the limits of interpreting images as mechanistic or therapeutic proof.

• Adipogenic Reprogramming in EMT-High PDAC

  2026-10-07

  A 2026 Cell Death and Disease study reports that adipogenic transdifferentiation can redirect EMT-high pancreatic ductal adenocarcinoma cells toward a lipid-rich, post-mitotic adipocyte-like state. The findings support a preclinical convert-instead-of-kill concept, while the model limitations mean that clinical relevance, durability, and safety remain unresolved.

• Galectin-1, FIP200, and Hepatic Steatosis

  2026-10-07

  A 2026 study identifies a Galectin-1–FIP200 interaction as a mechanistic link between impaired autophagy, hepatic steatosis, dyslipidemia, and insulin resistance. Its evidence connects animal phenotyping with proteomic, binding, structural, and mutation-based analyses, while its translational relevance remains limited by model and human-validation boundaries.

• Sucrose and the New Logic of Biomolecular Delivery

  2026-10-06

  A source-grounded perspective on condensate corona–nanoparticle complexes, what they reveal about rare-event biomolecular transfer, and how translational researchers should evaluate sucrose without confusing formulation relevance with demonstrated mechanism.

• D-Luciferin: Mechanism, Evidence, and Limits

  2026-10-06

  D-Luciferin is a firefly luciferase substrate used for bioluminescence imaging and ATP-linked reporter assays. Its reaction is sensitive, but photon output is a context-dependent proxy rather than a universal measure of cell number, gene expression, or intracellular ATP.

• Syringin and Sunitinib in Renal Cell Carcinoma

  2026-10-05

  A 2024 Journal of Functional Foods study presents Syringin as a candidate modulator of renal cell carcinoma biology and reports enhanced sunitinib activity in cell-based models. By combining network pharmacology, molecular docking, bioinformatics, functional assays, and pathway analysis, the authors associate these effects with EGFR/PI3K/Akt signaling, while the preclinical evidence remains insufficient to establish clinical efficacy.

• TAI-1 and RB1: A Cell-State View of Hec1 Targeting

  2026-10-05

  TAI-1 is a potent Hec1 inhibitor whose mitotic mechanism can be interpreted alongside new RB1-deficient retinal organoid findings. This article separates established pharmacology from forward-looking hypotheses about cell state, tumor origin, and biomarker-guided cancer research.

• Lithium, Exosomal Wnt10a, and Bone Repair

  2026-10-04

  A 2024 ACS Applied Materials & Interfaces study identifies a mechanistic link between lithium exposure, Rab11a-dependent exosomal Wnt10a secretion, and activation of β-catenin signaling in bone mesenchymal stem cells. Its findings suggest that lithium-engineered exosomes and GelMA-based delivery systems may improve osteogenic activity, while also defining important boundaries for translating the work beyond the reported cellular and animal models.

• Metoprolol Tartrate: Interpreting β1 Selectivity

  2026-10-03

  Metoprolol Tartrate is a selective β1-adrenergic blocking agent with applications spanning cardiovascular research and mechanistic hematopoiesis. This evidence-focused guide explains what recent transplant findings reveal—and what they do not prove—about receptor selectivity, tissue context, and study interpretation.

• Sucrose in Human Microglia Assay Workflows

  2026-10-02

  Sucrose can improve tissue-processing consistency in human microglia transplantation studies when its physical and osmotic effects are controlled. This guide connects sucrose handling to the hCSF1Bdes model and explains how pre-analytical choices influence microscopy, flow cytometry, and transcriptomic readouts.

• Safe DNA Gel Stain for Better Nucleic Acid Workflows

  2026-10-01

  Safe DNA Gel Stain supports sensitive DNA and RNA gel visualization while reducing reliance on ethidium bromide and UV exposure. This guide explains how to position it within a sensitivity-driven workflow, including RNA assay decisions, cloning, and practical protocol design.

• Ions Improve CPP–Nucleic Acid Delivery

  2026-10-01

  The reference study shows that biocompatible ions can reshape cell-penetrating peptide–nucleic acid nanoparticles and improve productive intracellular delivery, with multivalent ions exerting stronger effects than monovalent ions. Its key practical implication is that formulation-stage ion supplementation should be evaluated through particle properties, endosomal escape, and functional nucleic acid activity rather than internalization alone.

• GRK Control of Biased M1 Receptor Signaling

  2026-09-30

  A 2025 study used dynamic BRET measurements to define how GRK2/3 and GRK5/6 differentially regulate M1 receptor association with G proteins and β-arrestin 2. Its findings position GRK subtype balance, rather than receptor activation alone, as an important determinant of M1 signaling bias and clarify how BQCA changes acetylcholine responses.

• Annexin V-FITC/PI Apoptosis Assay Kit Guide

  2026-09-30

  The APExBIO Annexin V-FITC apoptosis kit helps researchers distinguish viable, early apoptotic, and membrane-compromised cells using phosphatidylserine externalization and PI uptake. It is suitable for cell-based flow cytometry or fluorescence microscopy, but should not be used alone to assign a specific death mechanism or for diagnostic decisions.

• EZ Cap™ Human PTEN mRNA (ψUTP): Lab Guide

  2026-09-29

  This scenario-based guide explains how SKU R1026 can help researchers standardize PTEN restoration experiments involving viability, proliferation, and cytotoxicity assays. It connects Cap 1 and pseudouridine-modified in vitro transcribed mRNA with practical controls, handling, delivery, and interpretation strategies.

8128 records 1/542 page Next 12345 下5页 Last page